ALT

Altimmune, Inc. [ALT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

ALT Stock Summary

Top 10 Correlated ETFs

ALT

Top 10 Correlated Stocks

ALT

In the News

ALT Financial details

Company Rating
-
Market Cap
566.45M
Income
-86.76M
Revenue
426K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
59
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-8.34
Forward P/E
-
PEG
7.94
P/S
2257
P/B
4.18
P/C
-
P/FCF
-11.24
Quick Ratio
12.24
Current Ratio
12.89
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.62
EPS next Y
-
EPS next Q
-
EPS this Y
-8.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
1.25%
Revenue last 5Y
-40.68%
Revenue Q/Q
-89.78%
EPS Q/Q
38.46%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-40%
Inst Own
-
Inst Trans
-
ROA
-45%
ROE
-45%
ROC
-0.55%
Gross Margin
61%
Oper. Margin
-30609%
Profit Margin
-27007%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.09-14.84
52W High
-81.21%
52W Low
+31.5%
RSI
38
Rel Volume
0.06
Avg Volume
5.18M
Volume
327.35K
Perf Week
-1.13%
Perf Month
-19.33%
Perf Quarter
-33.92%
Perf Half Y
-50.19%
-
-
-
-
Beta
0.059
-
-
Volatility
0.01%, 0.17%
Prev Close
0.38%
Price
2.63
Change
-0.38%

Something similar

Top by Market Cap
BRH.DE
DHR-PB
MIX.JO
FXAIX
MSFT
Top Correlated ETFs
LIT
HURA.TO
LITU.L
CLIX
FAN
Top Correlated Stocks
CRIS
ENA.WA
ALLO
BCYC
LTBR
Similar Market Cap
FLCO
0503.HK
ZENITHEXPO.NS
MUB.DE
STAR

Company Profile

Healthcare Biotechnology
  • Volume Average 5.18M
  • Market Capitalization 566.45M
  • Employee 59
  • CEO Dr. Vipin K. Garg Ph.D.
  • Headquarters Gaithersburg,MD,US
  • IPO Date 2017-05-26
  • Website https://altimmune.com

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.